103 completed, 23 unknown, 14 terminated, 5 withdrawn. 153 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 153 | Completed 103, Unknown 23, Terminated 14, Withdrawn 5, Recruiting 4, Not yet recruiting 2, Active not recruiting 1, Enrolling by invitation 1 |
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Iopidine to Decrease Intraocular Pressure Rise After Injections Apraclonidine 1.0% ophthalmic solution - Macular Degeneration, Diabetic Retinopathy | Phase 4 | Not yet recruiting | Retina Consultants of Delmarva | 120 | 2026-10-01 | 2026-10-23 |
| Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration Faricimab Injection [Vabysmo] - Macular Degeneration | Phase 4 | Recruiting | Junyeop Lee | 64 | 2026-06-29 | 2026-07-27 |
| Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material Vabysmo 6 MG in 0.05 ML Injection - Macular Degeneration, Age Related | Phase 4 | Recruiting | Biobizkaia Health Research Institute | 100 | 2026-05-25 | 2026-05-28 |
| Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia Iheezo, Lidocaine pledget - Macular Degeneration, Diabetic Retinopathy | Phase 4 | Completed | Retina Consultants of Delmarva | 50 | 2026-05-20 | 2026-08-21 |
| Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5% - Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD) | Phase 4 | Enrolling by invitation | Harrow Inc | 236 | 2026-03-31 | 2026-04-07 |
| Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization Intravitreal faricimab injection - Age-related Macular Degeneration (ARMD), Choroidal Neovascularization | Phase 4 | Not yet recruiting | Kim's Eye Hospital | 30 | 2025-09-23 | 2025-09-23 |
| Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment Anti-VEGF drug, Mecobalamin 5 MG, Placebo - Retinal Vein Occlusion (RVO) | Phase 4 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 120 | 2025-08-01 | 2026-02-27 |
| A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration avacincaptad pegol - Geographic Atrophy, Age-Related Macular Degeneration | Phase 4 | Active not recruiting | Astellas Pharma Inc | 17 | 2025-07-08 | 2026-10-30 |
| Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema. brolucizumab - Diabetic Macular Edema | Phase 4 | Completed | Novartis Pharmaceuticals | 66 | 2024-12-11 | 2026-04-13 |
| Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment Aflibercept 8mg - Age-related Macular Degeneration (ARMD) | Phase 4 | Completed | Kim's Eye Hospital | 35 | 2024-10-21 | 2026-07-16 |
| Ocular Safety and Usability Study for FYB203 PFS FYB203 2 mg (0.05 mL of 40 mg/mL) - Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema | Phase 4 | Completed | Formycon AG | 30 | 2024-09-20 | 2024-11-27 |
| Ocular Safety and Usability Study for FYB201 PFS FYB201 0.5 mg (0.05 mL of 10 mg/mL) - Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema | Phase 4 | Completed | Formycon AG | 31 | 2024-06-11 | 2024-11-27 |
| Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution - Corneal Edema, Corneal Defect | Phase 4 | Completed | Nicole Fram M.D. | 50 | 2023-06-01 | 2026-02-20 |
| Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery Bromfenac, Moxifloxacin 0.5% ophthalmic solution, Dexamethasone phosphate 0.1% - Cataract, Cystoid Macular Edema After Phacoemulsification | Phase 4 | Completed | Inas Abd | 87 | 2023-05-01 | 2025-05-06 |
| A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment Aflibercept(BAY86-5321, Eylea) - Neovascular (Wet) Age-related Macular Degeneration | Phase 4 | Terminated | Bayer | 3 | 2023-04-25 | 2024-10-16 |
| Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide - Exudative Age Related Macular Degeneration | Phase 4 | Withdrawn | Wake Forest University Health Sciences | 2023-03-30 | 2024-03-22 | |
| Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab Jueling Mingmu decoction, intravitreal injections of 0.5mg ranibizumab - Macular Cystoid Edema | Phase 4 | Completed | Dongyang People's Hospital | 111 | 2023-01-01 | 2025-08-22 |
| Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E Brolucizumab, Aflibercept - Age-Related Macular Degeneration | Phase 4 | Completed | The University of Hong Kong | 30 | 2022-07-25 | 2024-05-08 |
| Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) Injection Brolucizumab - Neovascular Age-related Macular Degeneration (nAMD) | Phase 4 | Completed | Novartis Pharmaceuticals | 105 | 2022-03-09 | 2025-03-20 |
| Cool vs Room-temperature Artificial Tears Refresh Plus Preservative-free Lubricant Eye Drops - Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema | Phase 4 | Completed | University of Iowa | 124 | 2022-03-01 | 2025-03-04 |
Showing 20 of 153. Sign in to see all of them.
Macular Degeneration (85) · Macular Edema (60) · Retinal Vein Occlusion (23) · Choroidal Neovascularization (18) · Wet Macular Degeneration (16) · Diabetic Retinopathy (12) · Vision Disorders (9) · Cataract (7) · Geographic Atrophy (7) · Diabetes Mellitus (5) · Polypoidal Choroidal Vasculopathy (5) · Retinal Detachment (4) · Retinal Diseases (4) · Uveitis (4)
Eye Diseases (150) · Retinal Diseases (149) · Macular Degeneration (65) · Cardiovascular Diseases (33) · Vascular Diseases (33) · Pathological Conditions, Signs and Symptoms (32) · Uveal Diseases (27) · Pathologic Processes (26) · Metaplasia (24) · Embolism and Thrombosis (23) · Neovascularization, Pathologic (23) · Thrombosis (23) · Venous Thrombosis (23) · Choroid Diseases (22)
Ranibizumab (49) · aflibercept (33) · Bevacizumab (10) · Calcium Dobesilate (9) · Verteporfin (9) · pegaptanib (8) · Dexamethasone (7) · Triamcinolone (7) · Photochemotherapy (5) · Ketorolac (4) · Triamcinolone Acetonide (4) · brolucizumab (4) · 1-phenyl-3,3-dimethyltriazene (3) · Ophthalmic Solutions (3) · bromfenac (3)
Novartis Pharmaceuticals (17) · Bayer (4) · Medical University of Vienna (4) · Allergan (3) · Asociación para Evitar la Ceguera en México (3) · Eyetech Pharmaceuticals (3) · Novartis (3) · Seoul National University Hospital (3) · Tennessee Retina (3) · Unity Health Toronto (3) · Università degli Studi di Brescia (3) · California Retina Consultants (2) · David M. Brown, M.D. (2) · Formycon AG (2) · Illinois Retina Associates (2)
United States (45) · Canada (12) · Germany (12) · South Korea (12) · United Kingdom (10) · Austria (9) · Japan (8) · China (7) · France (7) · Italy (7) · Spain (7) · Brazil (6) · Switzerland (6) · India (5) · Australia (4)
Brandon G Busbee, MD (2) · Christian Pruente, MD (2) · Rajeev Muni (2) · Rishi P Singh, MD (2) · Ursula Schmidt-Erfurth, MD (2) · Akiataka Tsujikawa, MD (1) · Alana M Santana, MD (1) · Alexander Kharlamov, M.D., Ph.D. (1) · Amod Gupta, MBBS MS (1)
PMID 11297486, PMID 11642370, PMID 12941734, PMID 12967792, PMID 15625332, PMID 17021318, PMID 17021319, PMID 17188044, PMID 17675159, PMID 18165083, PMID 18301024, PMID 1850220, PMID 18834580, PMID 1922252, PMID 19365036, PMID 19592101, PMID 20110127, PMID 20216291, PMID 20472746, PMID 21051706, PMID 21187730, PMID 21901296, PMID 22264944, PMID 22426346, PMID 22559899, PMID 22562296, PMID 22801846, PMID 22872673, PMID 22956609, PMID 23021093, PMID 23084240, PMID 23245386, PMID 23317655, PMID 23490325, PMID 23745581, PMID 24518078, PMID 24836866, PMID 25385061, PMID 25758601, PMID 25957377, PMID 25981599, PMID 26150052, PMID 26445522, PMID 26599244, PMID 26888975, PMID 27442130, PMID 28005662, PMID 28318636, PMID 28983556, PMID 29019795
2014 (4), 2009 (1), 2019 (1)